Skip to main content

Advertisement

SpringerLink
Log in

Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objectives: To investigate the safety and efficacy of docetaxel and zoledronic acid in patients with hormone-refractory prostate cancer (HRPC), based on preclinical evidence of synergism between taxanes and bisphosphonates. Methods: Twenty-five patients with advanced HRPC received weekly docetaxel 30 mg/m2: in 18 patients with symptomatic bone metastases and normal renal function, docetaxel was combined with zoledronic acid, 4 mg i.v. every 4 weeks. Premedication consisted of intravenous dexamethasone before docetaxel. No oral steroids were given. Results: Overall, 12 patients (48%) had a PSA response (reduction of 50% or more compared to baseline). A PSA response was achieved in 8/18 patients (44%) receiving concomitant docetaxel and zoledronic acid, and in 7/12 patients (58%) receiving docetaxel and zoledronic acid as first-line therapy. The weekly schedule of docetaxel resulted in a mean received dose intensity of 26 mg/m2/week, or 87% of the planned dose intensity. Toxicity was mild and as expected for docetaxel. The median time to progression was 7 months, and the median overall survival was 16 months. Conclusions: Concomitant treatment with docetaxel and zoledronic acid is safe and has encouraging activity in HRPC. The combination should be evaluated in randomised clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109

    Article  PubMed  CAS  Google Scholar 

  2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513

    PubMed  CAS  Google Scholar 

  3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  4. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26:14–18

    PubMed  CAS  Google Scholar 

  5. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19–23

    PubMed  CAS  Google Scholar 

  6. Hainsworth JD (2004) Practical aspects of weekly docetaxel administration schedules. The Oncologist 9:538–545

    Article  PubMed  CAS  Google Scholar 

  7. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8–15

    Article  PubMed  CAS  Google Scholar 

  8. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:273–279

    Article  Google Scholar 

  9. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, Genre D, Bardou VJ, Maraninchi D, Viens P (2003) Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98:1627–1634

    Article  PubMed  CAS  Google Scholar 

  10. Karavasilis V, Briasoulis E, Siarabi O, Pavlidis N (2003) Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer 2:46–49

    PubMed  CAS  Google Scholar 

  11. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Di Palma T, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G (2003) Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology 64:300–305

    Article  PubMed  CAS  Google Scholar 

  12. Kojima T, Shimazui T, Onozawa M, Tsukamoto S, Hinotsu S, Miyanaga N, Hattori K, Kawai K, Akaza H (2004) Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. Jpn J Clin Oncol 34:137–141

    Article  PubMed  Google Scholar 

  13. Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J (2004) A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 66:281–287

    Article  PubMed  CAS  Google Scholar 

  14. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  PubMed  CAS  Google Scholar 

  15. Senaratne SG, Mansi JL, Colston KW (2002) The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86:1479–1486

    Article  PubMed  CAS  Google Scholar 

  16. Coxon JP, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94:164–170

    Article  PubMed  CAS  Google Scholar 

  17. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI (2004) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126–1134

    Article  Google Scholar 

  18. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A (2003) Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 26:S92–S97

    Article  PubMed  Google Scholar 

  19. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461–3467

    PubMed  CAS  Google Scholar 

  20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  21. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:110

    Google Scholar 

  22. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 35:1502–1512

    Article  Google Scholar 

  23. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  24. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358–1365

    Article  PubMed  CAS  Google Scholar 

  25. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer Nov 23

  26. Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la Taille A (2004) Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 94:524–527

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported by GONO (Gruppo Oncologico Nord Ovest)

Author information

Authors and Affiliations

  1. Singleton Hospital, South West Wales Cancer Institute, Sketty, Swansea, SA2 8QA, UK

    Gianfilippo Bertelli

  2. Department of Medical Oncology, S.Croce General Hospital, Cuneo, Italy

    Abdelhamid Heouaine, Ornella Garrone, Ida Colantonio, Marcella Occelli, Elena Fea, Silvia Giubergia & Marco Merlano

  3. Department of Urology, S.Croce General Hospital, Cuneo, Italy

    Giuseppe Arena & Ambrogio Botto

Authors
  1. Gianfilippo Bertelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdelhamid Heouaine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Arena
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ambrogio Botto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ornella Garrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ida Colantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marcella Occelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elena Fea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Silvia Giubergia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marco Merlano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianfilippo Bertelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertelli, G., Heouaine, A., Arena, G. et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 57, 46–51 (2006). https://doi.org/10.1007/s00280-005-0025-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0025-4

Keywords

Search

Navigation